Recent Advances in Dengue

A special issue of Tropical Medicine and Infectious Disease (ISSN 2414-6366). This special issue belongs to the section "Neglected and Emerging Tropical Diseases".

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 12529

Special Issue Editors


E-Mail Website
Guest Editor
1. Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
2. Tropical Medicine Cluster, Chulalongkorn University, Bangkok 10330, Thailand
3. King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand
Interests: AKI epidemiology; resource-limited settings; novel biomarkers of AKI; tropical infections causing AKI; leptospirosis; dengue infection

E-Mail Website
Guest Editor
Tropical Medicine Cluster, Chulalongkorn University, Bangkok 10330, Thailand
Interests: dengue; other arboviruses; vaccines; pediatric infectious diseases; tropical infections; PMTCT of HIV; vaccine preventable diseases

E-Mail Website
Guest Editor
Tropical Medicine Cluster, Chulalongkorn University, Bangkok 10330, Thailand
Interests: dengue in adult; dengue vaccination and immune response

Special Issue Information

Dear Colleagues,

Dengue is a mosquito-borne viral disease found in tropical and sub-tropical climates worldwide. The disease significantly impacts global health. There has been a frightening increase in the number of dengue cases, from 505,430 in 2000 to 5.2 million in 2019, with about half of the world's population being at risk. Dengue causes a broad spectrum of diseases, ranging from subclinical to severe illnesses. Severe dengue is a leading cause of serious complications, including severe bleeding, organ impairment, plasma leakage, and death. Currently, there is no specific treatment for dengue. The World Health Organization (WHO) proposed a road map for the period of 2021–2030, with the global target for dengue control being to reduce preventable dengue deaths to zero and to reduce dengue incidence by 25%.  In line with the global targets, this Special Issue aims to provide coherent and comprehensive insights on updates on dengue research to continue the battle against dengue and to prepare for future outbreaks.

In this Special Issue, we encourage the submission of reviews or original research articles on the following scopes:

  1. Dengue pathogenesis—virus–host interactions;
  2. Dengue virology;
  3. Dengue diagnosis and biomarkers;
  4. Dengue vaccines and Immunology;
  5. Dengue antiviral research and development;
  6. Dengue epidemiology and climate change;
  7. Dengue vector control and surveillance;
  8. Severe dengue and clinical management.

Dr. Nattachai Srisawat
Prof. Dr. Usa Thisyakorn
Prof. Dr. Terapong Tantawichien
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Tropical Medicine and Infectious Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • dengue infection
  • dengue virus
  • diagnosis
  • biomarkers
  • vaccines
  • immunology
  • antiviral
  • epidemiology
  • vector control
  • surveillance

Published Papers (4 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Other

10 pages, 1294 KiB  
Article
Serum Cortisol as a Biomarker of Severe Dengue
by Chansuda Bongsebandhu-phubhakdi, Vichit Supornsilchai, Suphab Aroonparkmongkol, Umaporn Limothai, Sasipha Tachaboon, Janejira Dinhuzen, Watchadaporn Chaisuriyong, Supachoke Trongkamolchai, Mananya Wanpaisitkul, Chatchai Chulapornsiri, Anongrat Tiawilai, Thawat Tiawilai, Terapong Tantawichien, Usa Thisyakorn and Nattachai Srisawat
Trop. Med. Infect. Dis. 2023, 8(3), 146; https://doi.org/10.3390/tropicalmed8030146 - 27 Feb 2023
Viewed by 1724
Abstract
Dengue infection presents a wide range of clinical symptoms. Serum cortisol is known as a severity predictor of serious infection but is not yet clearly understood in dengue infection. We aimed to investigate the pattern of cortisol response after dengue infection and evaluate [...] Read more.
Dengue infection presents a wide range of clinical symptoms. Serum cortisol is known as a severity predictor of serious infection but is not yet clearly understood in dengue infection. We aimed to investigate the pattern of cortisol response after dengue infection and evaluate the possibility of using serum cortisol as the biomarker to predict the severity of dengue infection. This prospective study was conducted in Thailand during 2018. Serum cortisol and other laboratory tests were collected at four time points: day 1 at hospital admission, day 3, day of defervescence (DFV) (4–7 days post-fever onset), and day of discharge (DC). The study recruited 265 patients (median age (IQR) 17 (13, 27.5)). Approximately 10% presented severe dengue infection. Serum cortisol levels were highest on the day of admission and day 3. The best cut-off value of serum cortisol level for predicting severe dengue was 18.2 mcg/dL with an AUC of 0.62 (95% CI, 0.51, 0.74). The sensitivity, specificity, PPV and NPV were 65.4, 62.3, 16 and 94%, respectively. When we combined serum cortisol with persistent vomiting and day of fever, the AUC increased to 0.76. In summary, serum cortisol at day of admission was likely to be associated with dengue severity. Further studies may focus on the possibility of using serum cortisol as one of the biomarkers for dengue severity. Full article
(This article belongs to the Special Issue Recent Advances in Dengue)
Show Figures

Figure 1

9 pages, 531 KiB  
Article
Vitamin D Deficiency (VDD) and Susceptibility towards Severe Dengue Fever—A Prospective Cross-Sectional Study of Hospitalized Dengue Fever Patients from Lahore, Pakistan
by Somia Iqtadar, Amjad Khan, Sami Ullah Mumtaz, Shona Livingstone, Muhammad Nabeel Akbar Chaudhry, Nauman Raza, Mehreen Zahra and Sajid Abaidullah
Trop. Med. Infect. Dis. 2023, 8(1), 43; https://doi.org/10.3390/tropicalmed8010043 - 5 Jan 2023
Cited by 2 | Viewed by 5362
Abstract
Dengue is a mosquito-borne flaviviral serious febrile illness, most common in the tropical and subtropical regions including Pakistan. Vitamin D is a strong immunomodulator affecting both the innate and adaptive immune responses and plays a pivotal role in pathogen-defense mechanisms. There has been [...] Read more.
Dengue is a mosquito-borne flaviviral serious febrile illness, most common in the tropical and subtropical regions including Pakistan. Vitamin D is a strong immunomodulator affecting both the innate and adaptive immune responses and plays a pivotal role in pathogen-defense mechanisms. There has been considerable interest in the possible role of vitamin D in dengue viral (DENV) infection. In the present prospective cross-sectional study, we assessed a possible association between serum vitamin D deficiency (VDD) and susceptibility towards severe dengue fever (DF) illness. Serum vitamin D levels were measured at the time of hospitalization in 97 patients diagnosed with dengue fever (DF), dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS) at Mayo Hospital, King Edward Medical University, Lahore, PK, from 16 November 2021 to 15 January 2022. In terms of disease severity, 37 (38.1%) patients were DF, 52 (53.6%) were DHF grade 1 and 2, and 8 (8.2%) were DSS. The results revealed that most patients (75 (77.3%)) were vitamin-D-deficient (i.e., serum level < 20 ng/mL), including 27 (73.0%) in DF, 41 (78.8%) in DHF grade 1 and 2, and 7 (87.5%) in DSS. The degree of VDD was somewhat higher in DSS patients as compared to DF and DHF grade 1 and 2 patients. Overall, serum vitamin D levels ranged from 4.2 to 109.7 ng/mL, and the median (IQR) was in the VDD range, i.e., 12.2 (9.1, 17.8) ng/mL. Our results suggest that there may be a possible association between VDD and susceptibility towards severe dengue illness. Hence, maintaining sufficient vitamin D levels in the body either through diet or supplementation may help provide adequate immune protection against severe dengue fever illness. Further research is warranted. Full article
(This article belongs to the Special Issue Recent Advances in Dengue)
Show Figures

Figure 1

11 pages, 482 KiB  
Article
Assessment of Post-Dengue Rheumatic Symptoms Using the WOMAC and DAS-28 Questionnaires in a Honduran Population after a Four-Month Follow-Up
by Lysien I. Zambrano, Itzel Carolina Fuentes-Barahona, Ricardo Portillo-Pineda, Melissa Aguilar-Ponce, José Carlos Murillo-Padilla, Marlen Suazo-Menocal, Cesar Antunez-Salgado, Edissa Medina-Bassilet, Fausto Muñoz-Lara, D. Katterine Bonilla-Aldana, Juan J. Montenegro-Idrogo and Alfonso J. Rodríguez-Morales
Trop. Med. Infect. Dis. 2022, 7(12), 394; https://doi.org/10.3390/tropicalmed7120394 - 23 Nov 2022
Cited by 3 | Viewed by 2615
Abstract
Introduction: Alphaviruses may cause arthritis, but there is a lack of studies assessing it in flaviviruses such as dengue. Through the 28 Joint Disease Activity Score (DAS-28), incorporating swollen joint counts, and through the Arthritis Index from Western Ontario and McMaster Universities (WOMAC), [...] Read more.
Introduction: Alphaviruses may cause arthritis, but there is a lack of studies assessing it in flaviviruses such as dengue. Through the 28 Joint Disease Activity Score (DAS-28), incorporating swollen joint counts, and through the Arthritis Index from Western Ontario and McMaster Universities (WOMAC), we assessed pain, stiffness, and dimensions of arthritic function in post-DENV patients. Methods: Prospective study of a cohort of participants who were diagnosed with dengue in centres in Honduras from December 2019 to February 2020, with a follow-up period of 4 months to evaluate post-dengue rheumatological disease through the WOMAC and DAS-28 questionnaires. Results: After a four-month follow-up phase with 281 participants, the final cohort comprised 58.8% women and 41.20% men. After the follow-up, 63.02% persisted with the clinical findings. According to WOMAC, joint involvement was higher in women with (58.76%) (p < 0.0001) these symptoms or functional limitations when performing daily activities were limited to pain when walking (34.81% vs. 5.51%), climbing or descending stairs (36.46% vs. 8.66%), and at night at bedtime (28.73% vs. 7.08%). With the DAS-28, we found at least one alteration with inflammation or pain in 14.91% of the participants, primarily women (p < 0.01). Discussion: Joint involvement was high during the dengue epidemic in 2019. We observed a significant proportion of women with inflammation and joint pain, showing that dengue may lead to the development of chronic rheumatological findings, although lower than in CHIKV, still affecting everyday life and, consequently, their quality of life. Additional long-term evaluation studies after dengue are required. Full article
(This article belongs to the Special Issue Recent Advances in Dengue)
Show Figures

Figure 1

Other

Jump to: Research

8 pages, 686 KiB  
Conference Report
Proceedings of the 5th Asia Dengue Summit
by Nattachai Srisawat, Duane J. Gubler, Tikki Pangestu, Usa Thisyakorn, Zulkifli Ismail, Daniel Goh, Maria Rosario Capeding, Lulu Bravo, Sutee Yoksan, Terapong Tantawichien, Sri Rezeki Hadinegoro, Kamran Rafiq, Valentina Sanchez Picot and Eng Eong Ooi
Trop. Med. Infect. Dis. 2023, 8(4), 231; https://doi.org/10.3390/tropicalmed8040231 - 19 Apr 2023
Cited by 1 | Viewed by 1839
Abstract
The 5th Asia Dengue Summit, themed “Roll Back Dengue”, was held in Singapore from 13 to 15 June 2022. The summit was co-convened by Asia Dengue Voice and Action (ADVA), Global Dengue and Aedes transmitted Diseases Consortium (GDAC), Southeast Asian Ministers of Education [...] Read more.
The 5th Asia Dengue Summit, themed “Roll Back Dengue”, was held in Singapore from 13 to 15 June 2022. The summit was co-convened by Asia Dengue Voice and Action (ADVA), Global Dengue and Aedes transmitted Diseases Consortium (GDAC), Southeast Asian Ministers of Education Tropical Medicine and Public Health Network (SEAMEO TROPMED), and the Fondation Mérieux (FMx). Dengue experts from academia and research and representatives from the Ministries of Health, Regional and Global World Health Organization (WHO), and International Vaccine Institute (IVI) participated in the three-day summit. With more than 270 speakers and delegates from over 14 countries, 12 symposiums, and 3 full days, the 5th ADS highlighted the growing threat of dengue, shared innovations and strategies for successful dengue control, and emphasized the need for multi-sectoral collaboration to control dengue. Full article
(This article belongs to the Special Issue Recent Advances in Dengue)
Show Figures

Figure 1

Back to TopTop